Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Metrifonate treatment of AD: influence of APOE genotype.

Neurology - 10 Dec 1999

Farlow M R, Cyrus P A, Nadel A, Lahiri D K, Brashear A, Gulanski B

Abstract excerpt

OBJECTIVE: To investigate whether an interaction exists between APOE genotype and the response of AD patients to metrifonate treatment and whether APOE genotype independently affects the rate of AD progression. BACKGROUND: Metrifonate is a new acetylcholinesterase inhibitor for the treatment of AD symptoms. METHODS: Data were pooled from four prospective, randomized, double-blind, placebo-controlled clinical...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Aged, 80 and over
Share to Alzheimer Disease
Share to Apolipoproteins E

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Cholinesterase Inhibitors

Share to Dose-Response Relationship, Drug

Share to Double-Blind Method

Share to Drug Administration Schedule

Share to Treatment Outcome

Source

Identifiers

PMID: 10599773
DOI: 10.1212/wnl.53.9.2010

Genes

APOE

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Metrifonate treatment of AD: influence of APOE genotype.PMID 10599773Read ↗

APOE-ɛ4 Carrier Status and Donepezil Response in Patients with Alzheimer's Disease.Semantic proximity Read ↗

Lack of influence of the apolipoprotein E genotype on the outcome of selegiline treatment in Alzheimer's disease.Semantic proximity Read ↗

Medial temporal lobe atrophy and APOE genotype do not predict cognitive improvement upon treatment with rivastigmine in Alzheimer's disease patients.Semantic proximity Read ↗

Effect of Apolipoprotein E ɛ4 Carrier Status on Cognitive Response to Acetylcholinesterase Inhibitors in Patients with Alzheimer's Disease: A Systematic Review and Meta-Analysis.Semantic proximity Read ↗

BCHE and CYP2D6 genetic variation in Alzheimer's disease patients treated with cholinesterase inhibitors.Semantic proximity Read ↗

APOE genotype: no influence on galantamine treatment efficacy nor on rate of decline in Alzheimer's disease.Semantic proximity Read ↗

Apolipoprotein E genotype and gender influence response to tacrine therapy.Semantic proximity Read ↗

Impact of apolipoprotein E genotypes on vitamin E and memantine treatment outcomes in Alzheimer's diseaseSemantic proximity Read ↗

Presence or absence of at least one epsilon 4 allele and gender are not predictive for the response to donepezil treatment in Alzheimer's disease.Semantic proximity Read ↗

Effect of <i>APOE</i> genotype status on targeted clinical trials outcomes and efficiency in dementia and mild cognitive impairment resulting from Alzheimer's diseaseSemantic proximity Read ↗

Effect of the CYP2D6 and APOE Polymorphisms on the Efficacy of Donepezil in Patients with Alzheimer's Disease: A Systematic Review and Meta-Analysis.Semantic proximity Read ↗

Response to rivastigmine transdermal patch or memantine plus rivastigmine patch is affected by apolipoprotein E genotype in Alzheimer patients.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.